Bioclinica Enters Agreement to be Acquired by Cinven

Article

Bioclinica has signed an agreement to be acquired by international private equity firm Cinven.

Bioclinica has signed an agreement to be acquired by international private equity firm Cinven. The Pennsylvania-based clinical trial technology and services company, which this year reorganized into three core business segments, will mark the first investment from the Sixth Cinven Fund, which is targeting assets that can strategically drive growth in Europe and globally.

Read the full release here

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.